

## United States Patent and Trademark Office



| APPLICATION NO.   | FILING DATE   | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO.     | CONFIRMATION NO. |
|---|---------------|----------------------|-------------------------|------------------|
| 09/194,356  | 09/02/1999    | DARIO NERI           | 515-4132                | 3100             |
| 23599 75  | 90 04/30/2003 |                      |                         |                  |
| MILLEN, WHITE, ZELANO & BRANIGAN, P.C.<br>2200 CLARENDON BLVD.<br>SUITE 14700 |               |                      | EXAMINER                |                  |
|   |               |                      | HARRIS, ALANA M         |                  |
| ARLINGTON,  | VA 22201      |                      | ART UNIT                | PAPER NUMBER     |
|   |               |                      | 1642                    | 71               |
|   |               |                      | DATE MAILED: 04/30/2003 | 34               |
|   |               |                      |                         |                  |

Please find below and/or attached an Office communication concerning this application or proceeding.

## Advisory Action

raised by the Examiner in the final rejection.

10. Other: Interview Summary, Paper number 32

| Application No.        | Applicant(s) |
|------------------------|--------------|
| 09/194,356             | NERI ET AL.  |
| Examin r               | Art Unit     |
| Alana M. Harris, Ph.D. | 1642         |

-- The MAILING DATE of this communication appears n the cover sheet with the corresp ndence address --

THE REPLY FILED 15 April 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

| PERIOD FOR REPLY [check either a) or b)]   |
|--|
| a) The period for reply expiresmonths from the mailing date of the final rejection.  |
| b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.  ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).   |
| Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). |
| 1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.   |

| 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.   |
|--|
| 2. The proposed amendment(s) will not be entered because:  |
| (a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);   |
| (b) ☐ they raise the issue of new matter (see Note below);   |
| (c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or   |
| (d) They present additional claims without canceling a corresponding number of finally rejected claims.  |
| NOTE:  |
| B. Applicant's reply has overcome the following rejection(s): <u>See Continuation Sheet</u> .  |
| 4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).                                      |
| 5.⊠ The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet. |
| 6 The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly   |

|    | explanation of how the new or amended claims would be rejected is provided below or appended. |
|----|---|
|    | The status of the claim(s) is (or will be) as follows:  |
|    | Claim(s) allowed:   |
|    | Claim(s) objected to: 38-42 and 46.   |
|    | Claim(s) rejected: <u>30-37,43-45,47 and 53-57</u> .  |
|    | Claim(s) withdrawn from consideration:  |
|    | The proposed drawing correction filed on is a) approved or b) disapproved by the Examiner.    |
| 9. | Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s).                 |

7. For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an

PATENT EXAMINER

131 2013

4

Continuation of 3. Applicant's reply has overcome the following rejection(s): claims 30-37, 43-45, 47 and 53-57 rejected under 35 U.S.C. 112, first paragraph (paragraph 16 of Paper number 31) and claim 47 rejected under 35 U.S.C. 112, second paragraph (paragraph 18 of said paper).

Continuation of 5. does NOT place the application in condition for allowance because: in a broad interpretation of the claims the art does not preclude the prior art of the European Patent number 0 344 134 from reading on an antibody or antibody fragment which binds to both, the epitope in homology repeat 7 and recombinant FN containing type III homology repeats which include the ED-B domain. Specifically, claim 34 does not preclude the disclosed BC-1 antibody from binding the ED-B domain within the type III homology repeat.